Randomized controlled trials (RCTs) play a central role in medical research by helping researchers evaluate the effectiveness and safety of medicines, medical devices, surgical procedures, preventive strategies, and other healthcare interventions. However, conducting a well-designed clinical trial is only one part of producing reliable scientific evidence. Researchers must also report their methods, findings, and limitations transparently so that readers can assess the validity and relevance of the results.

The Consolidated Standards of Reporting Trials (CONSORT) guidelines provide a structured framework for reporting randomized trials. They help authors explain how participants were recruited, how randomization was performed, which interventions were administered, how outcomes were measured, and what the study ultimately found.

As of 2026, researchers should consult the CONSORT 2025 Statement, which supersedes the widely used CONSORT 2010 Statement. The updated guideline contains a 30-item checklist and a participant flow diagram, with a stronger emphasis on open science, trial registration, access to protocols, data sharing, and transparent reporting.

Understanding the current CONSORT framework is particularly important for clinical researchers, postgraduate students, medical writers, statisticians, and authors preparing manuscripts for peer-reviewed journals.

What Are the CONSORT Guidelines?

CONSORT is an evidence-informed reporting guideline developed to improve the completeness and transparency of reports describing randomized trials. It provides a common structure for communicating the essential information readers need to understand a study and evaluate its findings.

The guideline focuses on reporting rather than prescribing how every trial must be designed or conducted. It does not replace a clinical trial protocol, statistical analysis plan, research ethics requirements, or applicable regulatory standards.

CONSORT primarily addresses randomized trials, particularly individually randomized, two-group parallel trials. Researchers conducting other trial designs may need to consult additional CONSORT extensions.

The framework has two central components:

  • CONSORT checklist: Identifies the essential information that should be included in a randomized trial report.
  • CONSORT flow diagram: Illustrates participant progression through enrolment, allocation, follow-up, and analysis.

Together, these components help make a clinical trial report easier to interpret, reproduce where appropriate, and assess critically.

Why Are CONSORT Guidelines Important in Medical Research?

Incomplete reporting can make even a promising clinical trial difficult to evaluate. For example, a manuscript may report that a new medication improved patient outcomes without explaining how participants were allocated, whether outcome assessors were blinded, or how missing observations were handled.

Without these details, readers cannot fully assess the possibility of bias or determine how confidently the results can inform clinical decisions.

CONSORT supports transparent reporting in several ways.

1. Improves reporting completeness

The checklist reminds authors to report essential methodological details, trial outcomes, participant numbers, adverse events, and other relevant information. This reduces the likelihood of omitting important details during manuscript preparation.

2. Helps readers assess potential bias

Reporting randomization, allocation concealment, blinding, and the handling of missing data allows readers to examine possible sources of bias. CONSORT does not eliminate bias by itself. Rather, it helps authors describe the methods used so that readers can evaluate their implications.

3. Strengthens interpretation of trial findings

Clearly reported outcome measures, effect estimates, confidence intervals, and adverse events help readers understand both the potential benefits and the possible harms of an intervention.

4. Supports evidence synthesis

Systematic reviewers and meta-analysts need sufficiently detailed reports to identify relevant studies and extract comparable information. Transparent trial reporting can therefore support evidence synthesis and future research.

5. Facilitates editorial and peer review

A well-structured manuscript makes it easier for reviewers and editors to assess whether the study's methods, analyses, and conclusions are reported consistently.

Researchers should remember that following CONSORT does not guarantee acceptance by a journal. Publication decisions also depend on scientific merit, methodological rigour, relevance, ethical compliance, and the journal's scope.

Medical Journal IMJ Health Call for Papers

Understanding the CONSORT 2025 Checklist

The CONSORT 2025 Statement contains 30 checklist items covering the major elements of a randomized trial report. These items are organised around essential reporting information, including the trial's identification, scientific rationale, methods, findings, interpretation, and open-science practices.

The following sections explain the main areas authors should address when preparing a manuscript.

1. Title and Abstract

The title should clearly identify the study as a randomized trial. This helps readers and database users recognise the research design when searching the scientific literature.

The abstract should provide a structured and balanced summary of the trial, including its objectives, design, methods, principal results, and conclusions. Authors should report key numerical findings rather than relying on general statements about whether the intervention was successful.

A useful abstract should communicate:

  • The research question and trial design
  • The participants and interventions being compared
  • The primary outcome and important results
  • The main conclusion, interpreted in light of the findings

For example, rather than stating that a new intervention was highly effective, researchers should report the observed outcome in each group and an appropriate measure of the difference between groups, with its uncertainty where available.

2. Scientific Background and Objectives

The introduction should explain why the trial was necessary. Authors should summarise relevant evidence, identify the knowledge gap, and establish the scientific rationale for evaluating the intervention.

The research objectives or hypotheses should be clearly stated.

For example, a trial investigating a new blood-pressure medication might aim to compare its effect on systolic blood pressure with that of an established treatment after 12 weeks.

A clearly defined objective helps readers understand the relationship between the original research question, the selected outcome measures, and the reported findings.

3. Trial Design and Methods

The methods section is one of the most important parts of a randomized trial report. It should contain enough information for readers to understand how the trial was planned and conducted.

Trial design: Describe whether the study used a parallel-group, factorial, cluster-randomized, crossover, or another design. State the allocation ratio and explain any important changes made after the trial began, including their reasons.

Participants and setting: Specify eligibility criteria, recruitment procedures, study locations, and relevant dates. Explain who could participate and how potential participants were identified.

Interventions: Describe each intervention in sufficient detail for readers to understand what participants received. Include relevant information about dosage, timing, frequency, duration, delivery, and comparator treatments.

Outcomes: Identify the primary and secondary outcomes, how they were measured, and when assessments took place. Explain any changes to the originally planned outcomes and why they occurred.

Sample size: Explain how the target number of participants was determined. The report should identify the assumptions used in the calculation, such as the anticipated treatment effect, variability, statistical power, and significance level, where applicable.

These details allow readers to determine whether the study methods align with its stated objectives.

4. Randomization and Allocation Concealment

Randomization is a defining feature of an RCT. It involves assigning eligible participants to trial groups through a random process intended to reduce systematic differences between groups at baseline.

However, authors should distinguish between the generation of a random sequence and the concealment of that sequence during participant enrolment.

The report should explain:

  • How the random allocation sequence was generated
  • What method was used to implement randomization
  • Whether allocation was concealed until participants were assigned
  • Who generated the sequence, enrolled participants, and assigned interventions, where relevant
  • Whether restrictions such as blocking or stratification were used

For example, a trial might use a computer-generated random sequence and a secure allocation system managed independently of the person recruiting participants.

Simply stating that participants were randomly assigned is not enough to explain how the process worked.

5. Blinding and Bias Prevention

Blinding refers to keeping certain people unaware of participants' assigned interventions when this is feasible and appropriate. Depending on the trial, these individuals may include participants, healthcare providers, outcome assessors, and data analysts.

Authors should explain who was blinded and how blinding was implemented. If blinding was not possible, the report should acknowledge this and describe relevant safeguards against bias.

For example, a surgical trial may be unable to blind the operating surgeon, but independent assessors might evaluate outcomes without knowing which intervention each participant received.

Blinding should not be confused with allocation concealment. Allocation concealment protects the assignment process before or at enrolment, whereas blinding concerns knowledge of treatment assignment after allocation.

6. Statistical Methods

The statistical analysis section should explain how the researchers analysed the collected data and evaluated the trial's outcomes.

Authors should identify the methods used for the primary and secondary outcomes, explain how treatment effects were estimated, and describe any planned subgroup or additional analyses.

The report should also address relevant issues such as:

  • The analysis population and whether an intention-to-treat approach was used
  • How missing data were handled
  • Whether adjusted analyses were performed and which variables were included
  • How multiple outcomes or comparisons were addressed, when relevant
  • Any departures from the original statistical analysis plan

Researchers should distinguish analyses that were prespecified from those developed after examining the data. This helps readers understand the strength of the evidence and the possibility of selective reporting.

Reporting Results According to CONSORT

A transparent results section should explain what happened during the trial and present the findings in a balanced, interpretable manner.

1. Participant Recruitment and Progress

Authors should report the number of participants assessed for eligibility, excluded before randomization, randomized to each group, receiving the intended intervention, followed up, and included in each analysis, as applicable.

Reasons for exclusions, withdrawal, loss to follow-up, and other relevant departures from the planned study should be described.

The participant flow diagram is particularly useful because it presents these numbers visually and allows readers to trace participant progression through the trial.

2. Baseline Characteristics

A baseline characteristics table can summarise relevant demographic and clinical information for each randomized group. Depending on the research question, these characteristics may include age, sex, disease severity, medical history, and other important prognostic variables.

Baseline tables should describe the observed groups without treating statistical tests of baseline differences as proof that randomization succeeded or failed. Randomization is evaluated through the allocation process, not by whether baseline significance tests produce particular p-values.

3. Primary and Secondary Outcomes

The primary outcome should receive clear and complete reporting. Authors should present the results for each group and the estimated between-group effect, together with a measure of precision such as a confidence interval where appropriate.

For example, a trial comparing two interventions for blood-pressure control might report mean changes in systolic blood pressure in both groups, the estimated difference between groups, and its 95% confidence interval.

A p-value alone does not show the size or clinical importance of an effect. Authors should therefore report effect estimates and their uncertainty whenever appropriate, and interpret findings in the context of the research question.

Secondary outcomes should also be reported transparently, including findings that do not support the original hypothesis.

4. Adverse Events and Unintended Effects

Safety reporting is essential, especially in trials involving medicines, devices, or invasive procedures.

Authors should describe the adverse events and other unintended effects assessed during the study, explain how they were collected, and report relevant findings by group. The presentation should include denominators and appropriate measures of frequency or effect.

A manuscript should not emphasise potential benefits while omitting relevant harms. If the study was not designed or powered to assess uncommon adverse events, this limitation should be stated.

5. Discussion and Interpretation

The discussion should interpret the findings without exaggerating their implications.

Authors should relate the results to previous evidence, explain the study's strengths and limitations, consider potential sources of bias, and discuss the relevance of the findings to clinical practice or future research.

The conclusion should reflect the actual results, including uncertainty. A statistically significant result does not automatically demonstrate a clinically meaningful benefit, while a nonsignificant result does not necessarily prove that two interventions are equivalent.

Researchers should also consider generalisability: whether the participants, intervention, setting, and follow-up period resemble the circumstances in which the findings might be applied.

CONSORT 2025 and Open Science

An important feature of the updated CONSORT 2025 Statement is its dedicated emphasis on open-science reporting. Researchers should provide clear information about trial registration, access to protocols and statistical analysis plans, data-sharing arrangements, and funding or competing interests.

Trial registration

The manuscript should identify the trial registry, registration number, registration date, and relevant registry URL. Registration information helps readers locate the trial record and compare the reported study with its registered details.

Registration should be accurate and should not be presented as proof that every aspect of the trial was conducted appropriately.

Protocol and statistical analysis plan

Authors should explain where the trial protocol and statistical analysis plan can be accessed. These documents help readers understand the planned methods and assess whether changes or additional analyses occurred.

If documents are not publicly available, authors should state the situation accurately rather than implying that they can be accessed.

Data sharing

The report should explain whether and how deidentified participant-level data, the data dictionary, statistical code, and other relevant materials can be accessed.

Any sharing arrangements should be consistent with participant consent, privacy protections, ethics approvals, and applicable legal requirements. Authors should clearly describe access conditions and restrictions.

Funding and competing interests

Researchers should disclose funding sources, other material support, and the role of funders in trial design, conduct, analysis, and reporting.

Relevant financial and non-financial competing interests should also be declared in accordance with journal requirements.

These disclosures help readers assess the research context and understand how the study was supported.

How to Use the CONSORT Checklist Before Journal Submission

The checklist is most useful when it is incorporated into manuscript preparation rather than treated as a final administrative task.

Step 1: Identify the correct guideline. Begin with the official CONSORT 2025 checklist. Confirm whether the trial's design or intervention requires an additional extension.

Step 2: Review the study protocol and analysis plan. Compare the planned methods and outcomes with the completed trial and manuscript. Document important deviations and explain them accurately.

Step 3: Map checklist items to manuscript sections. Identify where each item is addressed in the title, abstract, introduction, methods, results, discussion, tables, figures, or supplementary materials.

Step 4: Verify numerical consistency. Cross-check participant numbers, denominators, outcome estimates, confidence intervals, p-values, and adverse-event counts across the abstract, main text, tables, and flow diagram.

Step 5: Check transparency requirements. Confirm that registration information, protocol access, data-sharing statements, funding disclosures, and competing-interest declarations are complete and accurate.

Step 6: Complete the submission checklist. Enter the page numbers or relevant locations where each item is reported, following the journal's instructions. If a particular item does not apply, follow the checklist and journal guidance for explaining this.

Step 7: Review journal-specific requirements. Some journals request a completed checklist, a flow diagram, or supplementary materials at submission. Follow the target journal's current instructions rather than assuming every journal uses identical requirements.

CONSORT and Other Medical Research Reporting Guidelines

CONSORT is designed specifically for reporting randomized trials. Other research designs require different reporting frameworks.

CONSORT: Randomized controlled trials.

STROBE: Observational studies, including cohort, case-control, and cross-sectional studies.

PRISMA: Systematic reviews and meta-analyses.

STARD: Diagnostic accuracy studies.

CARE: Case reports.

ARRIVE: Research involving animals.

Selecting the correct guideline is important because different study designs raise different reporting questions. A randomized trial should not use STROBE as a substitute for CONSORT simply because both guidelines address medical research.

The EQUATOR Network maintains resources for identifying reporting guidelines and relevant extensions. Researchers can consult its clinical trials reporting resources.

Common Mistakes When Applying CONSORT

Even experienced researchers may overlook important reporting requirements. Common mistakes include:

  • Using an outdated checklist: Applying CONSORT 2010 without checking the updated CONSORT 2025 Statement
  • Providing incomplete randomization details: Stating that allocation was random without explaining the sequence-generation and implementation procedures
  • Reporting only p-values: Omitting effect estimates, confidence intervals, or the actual results in each group
  • Ignoring missing data: Failing to explain participant losses, exclusions, or how missing observations were handled
  • Overlooking adverse events: Reporting effectiveness without adequately describing relevant safety findings
  • Failing to explain deviations: Omitting changes to methods, outcomes, or analyses made after the trial began
  • Submitting an incomplete flow diagram: Showing the number randomized without adequately accounting for follow-up and analysis
  • Treating checklist completion as a quality guarantee: Assuming that a completed checklist proves the trial was well designed or free from bias

The solution is to use the guideline alongside careful methodological documentation, statistical review, and journal-specific submission checks.

Practical Example: Applying CONSORT to a Randomized Clinical Trial

Imagine researchers conduct a randomized trial comparing a new treatment with standard care for adults with a particular chronic condition.

To report the study transparently, they would identify the research as a randomized trial in the title, explain the clinical rationale, and state the primary outcome. The methods would describe eligibility criteria, recruitment settings, intervention procedures, random sequence generation, allocation concealment, blinding where applicable, sample-size calculations, and statistical methods.

The results would show how many participants entered each group, how many completed follow-up, and how many were included in the relevant analyses. A flow diagram would help account for participant progression.

The researchers would then report the primary outcome in both groups, the estimated treatment effect, its uncertainty, and relevant adverse events. The discussion would consider limitations, applicability, and how the findings compare with previous research.

Finally, the manuscript would provide accurate trial registration details, access information for the protocol and analysis plan, data-sharing arrangements, funding sources, and competing-interest disclosures.

Using the CONSORT 2025 checklist throughout this process would help the team identify missing information before submission. It would not, by itself, establish that the intervention works or that the trial is methodologically sound.

The CONSORT guidelines provide an essential framework for reporting randomized controlled trials transparently and completely. By following the CONSORT 2025 Statement, researchers can ensure that their manuscripts include the information readers, reviewers, and editors need to assess the validity and relevance of their findings.

From trial registration and protocol access to participant flow, outcome reporting, and open-science practices, CONSORT helps authors communicate their research in a structured and transparent manner. While following the guideline does not guarantee publication or prove methodological quality, it supports the production of more credible and useful medical evidence. For those considering doctoral research in this area, Top 10 Pharmaceutical Research Topics for PhD offers guidance on selecting impactful research directions.

Continue Exploring Our Blog